ライフサイエンスコーパス: abdominal symptom

1 luids which resulted in faster resolution of abdominal symptoms.

2 ine percent of 521 HAE attacks only involved abdominal symptoms.

3 high prevalance of long-lasting fatigue and abdominal symptoms.

4 o the emergency department with non-specific abdominal symptoms.

5 ificant differences in the severity of other abdominal symptoms.

6 ccumulate intra-abdominal fat that may cause abdominal symptoms.

7 In July, 1995, the patient had recurrent abdominal symptoms.

8 ys rather than, for example, anxiety causing abdominal symptoms.

9 9, 23); all of these patients presented with abdominal symptoms.

10 er in patients presenting with 2 nonspecific abdominal symptoms.

11 (8.67%; 4.63%), other pain (11.60%; 7.19%), abdominal symptoms (15.58%; 8.29%), myalgia (3.24%; 1.54

12 The commonest indications were lower abdominal symptoms (275; 21%) followed by uncomplicated

13 giardiasis (CG), 66 patients with persistent abdominal symptoms after acute Giardia infection (PI-FGI

14 s and inflammatory bowel disease of 6 common abdominal symptoms among more than 1.9 million primary c

15 Abdominal symptoms and signs may be due to SLE or due to

16 easing stool frequency, positively affecting abdominal symptoms and well-being, and modulating the gu

17 Associations with illness duration, abdominal symptoms, and histology grade were assessed.

18 observed larger changes in stool frequency, abdominal symptoms, and particularly social and emotiona

19 e from baseline in daily bowel habits, daily abdominal symptoms, and weekly global assessments, in ad

20 All four subjects presented with abdominal symptoms at a mean of 6.1 years posttransplant

21 on GFD were associated with the presence of abdominal symptoms at the time of coeliac disease diagno

22 ght upper quadrant symptoms, (b) generalized abdominal symptoms, (c) unexplained sepsis, or (d) sepsi

23 Neutropenic patients with fever and abdominal symptoms (cramping, pain, distention, diarrhea

24 Abdominal symptoms decreased to seven of 56 patients (13

25 sparaginase-associated pancreatitis, risk of abdominal symptoms dropped from 8% (26 of 312) to 0% (0

26 in the year post-consultation with each of 6 abdominal symptoms: dysphagia (n = 86,193 patients), abd

27 were associated with long diagnostic delay, abdominal symptoms, female gender and impaired quality o

28 atients who had been using indinavir without abdominal symptoms for at least 6 months and ten HIV-1-i

29 al decisions, considering the PPVs of common abdominal symptoms for cancer alongside that for IBD and

30 out the positive predictive values (PPVs) of abdominal symptoms for different cancers and inflammator

31 into account the variable PPVs of different abdominal symptoms for different cancers sites.

32 d and sustained improvement of bowel habits, abdominal symptoms, global relief, and quality of life i

33 ed with selective liver enlargement and that abdominal symptoms in ADPKD patients may be because of e

34 linaclotide significantly reduced bowel and abdominal symptoms in patients with chronic constipation

35 Among adult patients presenting with abdominal symptoms in primary care or other unselected p

36 The diagnostic assessment of abdominal symptoms in primary care presents a challenge.

37 s variable and most patients presenting with abdominal symptoms in primary care will not have celiac

38 Fifteen patients presenting with unspecific abdominal symptoms in which food allergy was detected in

39 of linaclotide significantly improved other abdominal symptoms, including discomfort and bloating, a

40 D), a common disorder characterized by upper abdominal symptoms, including discomfort or postprandial

41 While her abdominal symptoms mildly improved with ustekinumab, she

42 atigue/malaise, chest/throat pain, headache, abdominal symptoms, myalgia, other pain, cognitive sympt

43 ctal bleeding (OR, 0.28; 95% CI, 0.20-0.40), abdominal symptoms (OR, 0.15; 95% CI, 0.10-0.21), or oth

44 register of Sweden, were given the validated Abdominal Symptom Questionnaire 1998-2001; 1000 of these

45 sophagogastroduodenoscopy and were given the Abdominal Symptom Questionnaire along with the Hospital

46 In patients consulting with nonspecific abdominal symptoms, the assessment of cancer risk based

47 gn, enrolled adults presenting with nonacute abdominal symptoms, the prevalence of celiac disease was

48 in ten HIV-1-positive patients who had such abdominal symptoms to measure total adipose tissue (TAT)

49 The performance of abdominal symptoms varied widely.

50 frequency of colorectal-cancer screening and abdominal symptoms was similar in the two groups.

51 istribution of disease, and association with abdominal symptoms were all analyzed.

52 ydrate malabsorption), flatus frequency, and abdominal symptoms were assessed after subjects ingested

53 The most commonly reported abdominal symptoms were distension (77%), cramping (73%)

54 rmality in 109 of the 120 patients (91%) and abdominal symptoms were present in 104 of the 109 (95%).

55 tifying patients presenting with nonspecific abdominal symptoms who have underlying cancer is a chall

56 The presentation included mild abdominal symptoms with rapid progression of peritonitis

57 ut half of the patients had to discuss their abdominal symptoms with their general practitioner (GP)

58 nal dyspepsia (FD) is characterized by upper abdominal symptoms without organic disease manifestation